Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
May 02 2023 - 4:01PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the
“Company”), a clinical-stage biopharmaceutical company developing a
novel therapeutic that targets toxic soluble amyloid beta oligomers
(AβOs) for the treatment of Alzheimer’s disease, today announced
that the Company will report first quarter financial results on
Tuesday, May 9, 2023. The Company will host a conference call and
live audio webcast at 8:00 a.m. ET to provide a business and
financial update.
To participate in the live conference call, please register
using this link. After registration, you will be informed of the
dial-in numbers including PIN. Please register at least one day in
advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company's website
at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical
operations based in Carmel, IN, is a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers (AβOs) for the
treatment of Alzheimer’s disease (AD). Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are early and persistent triggers of Alzheimer’s disease
pathology. Acumen is currently focused on advancing its
investigational product candidate, ACU193, a humanized monoclonal
antibody that selectively targets toxic soluble AβOs in
INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s
disease patients. For more information,
visit www.acumenpharm.com.
Investors: Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jul 2023 to Jul 2024